Drug Discovery Today
JULY 1, 2022
Barclays has selected Discovery Park in Kent as the home for its latest Eagle Lab which will open later this year. The lab will help facilitate collaboration between the Life Sciences and Technology sectors, with the aim of driving development of a community base focused on clean energy, agri-tech and addressing future challenges in healthcare.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JUNE 29, 2022
I can’t recall any period in my life when our country has been so divided and polarized. Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage—along with links to source materials so you can make up your own mind. So before you launch your July 4 festivities and/or a civil war, Drug Channels humbly offers some data fireworks for our troubled nation: More evidence of slow growth in drug spending for 2021 Fresh data on skyrocketing PBM formulary exclusi
Pharma Manufacturing
JUNE 28, 2022
Advanced digital thread and technology transfer capabilities can help pharma reap the benefits of its processes
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Altus Drug Development
JUNE 30, 2022
A focus on customers has always been one of the main pillars of the pharmaceutical industry. However, this is often narrowed down to the creation of product-centric marketing strategies with a strong customer orientation. While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. The integration of value-added services and strategies provides a new perspective on patient care.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Advarra
JUNE 30, 2022
The post Expanding the Ecosystem to Better Serve You appeared first on Advarra.
ProRelix Research
JUNE 29, 2022
According to the World Health Organization (WHO), cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (1). In addition, GLOBACAN estimated 19.3 […]. The post Oncology Bioequivalence Clinical Studies appeared first on ProRelix Research.
Crown Bioscience
JUNE 28, 2022
Precision medicine and immunotherapy continue to top the list as two of the hottest areas in cancer research. In this blog post we explore how immuno-oncology can draw from precision medicine to create more personalized cancer therapies to enhance their safety and efficacy. Read on to review how ICIs, neoantigen vaccines and adoptive cell therapies, including CAR-T, CAR-NK, CAR-M, TCR-T and TIL therapies, are advancing this remarkable field of science and medicine.
Drug Patent Watch
JUNE 30, 2022
Annual Drug Patent Expirations for LUSEDRA Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent expiration for Eisai Inc drug LUSEDRA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Altus Drug Development
JUNE 28, 2022
Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine? Value-added medicines are novel drug products created to provide improvements for patients that can’t be achieved using traditional therapeutic methods.
Advarra
JUNE 28, 2022
As a drug successfully makes it through the development process, sponsors will inevitably need to submit a new drug application (NDA) to the Food and Drug Administration (FDA). While it may seem like a straightforward process to some, there’s room for many elements to be missed as sponsors prepare for the application submission. Failure to Have a Pre-Investigational New Drug (IND) Meeting.
Olympian Clinical Research
JUNE 28, 2022
Prurigo nodularis is a skin condition characterized by the development of small nodular lesions, which are often severely itchy. People afflicted with this disease may develop a few lesions or potentially over 200, all of which with varying sizes. Often confused with other skin conditions, prurigo nodularis symptoms may resemble eczema or psoriasis, making it challenging to diagnose and treat. .
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for LICART Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA. The generic ingredient in LICART is diclofenac epolamine. Additional…. The post New patent for Ibsa Inst drug LICART appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Crown Bioscience
JUNE 27, 2022
This article originally appeared on Labiotech.eu in July 2022 and is written by Alexander Burik. Large-panel cancer cell line screening can help find the right fit between a specific cancer cell and a therapeutic molecule, leading to the development of effective treatments. How can robust quality control, real-time screening methods, and a set of unique screening panels address current screening challenges?
sptlabtech
JUNE 27, 2022
"For the last couple of years, we've been Covid testing and have been very successful with the SPT Labtech liquid handlers." Farruk Kabir | NGS Lab Manager | Aperture NextGen Laboratories Aperture NextGen Laboratories is an FDA approved CLIA lab for interdisciplinary clinical testing and research. Over the course of the pandemic, the team of around 15 to 20 lab staff based in Plano, Texas, has been busy testing for SARS-CoV-2 and developing proprietary NGS protocols.
Atomwise Blog
JUNE 27, 2022
Our scientists have developed a set of chemical benchmarks to better understand exactly what our computational models are learning. At Atomwise, AtomNet® structure-based models can quickly identify active compounds for protein targets from large chemical libraries for drug discovery projects. Understanding how models recognize features of molecular activity can shed light on, for example, important receptor-ligand interactions, biases toward particular functional groups, or target selectivity of
Drug Patent Watch
JUNE 29, 2022
Annual Drug Patent Expirations for ORILISSA Orilissa is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Abbvie Inc drug ORILISSA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharma Manufacturing
JUNE 29, 2022
How pharma can build better facilities by leveraging digital information?
Drug & Device Law
JULY 1, 2022
We have a case going on where the plaintiff wants to preclude the use of a term found in his medical records to describe something that happened to him in the past that is highly relevant to the claims and injuries in the case. Instead of using the actual term, which was also used in treater depositions that will be played at trial—appropriately, because the term was in the records generated by those treaters—the plaintiff wants to use a substitute term that he finds less inflammatory.
Drug Patent Watch
JUNE 29, 2022
Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are thirty-five patents protecting this drug. This drug…. The post New patent for Amicus Therap drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 27, 2022
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
JUNE 30, 2022
This chart shows the pharmaceutical companies with the most patents in Australia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Australia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for WEGOVY Wegovy is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent for NOVO drug WEGOVY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 28, 2022
Annual Drug Patent Expirations for NOCTIVA Noctiva is a drug marketed by Serenity Pharms Llc and is included in one NDA. There are four patents protecting this drug. Drug patent…. The post New patent for Serenity Pharms drug NOCTIVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content